SCK CEN-NURA, NURA contributes to the development of the next-generation radiopharmaceuticals. More specifically, NURA performs game-changing research into radiopharmaceuticals for treating different types of cancer in cooperation with clinical and industrial partners.
Activities and description
As a Contract Research Organisation, we support clinical and pharmaceutical partners in the development of promising radiopharmaceuticals for therapeutic purposes by providing them with data to enter the next phase.
Focusing on the phases prior to clinical research, we offer interdisciplinary expertise and access to our unique pre-clinical research facilities, including:
- Radiolabelling labs
- Imaging equipment
- in-vitro/in-vivo tests/equipment
With over 70 years’ experience in nuclear research and life sciences, SCK CEN can deliver the perfect, tailor-made research programme. We place a specialist team at your service and give you access to our considerable infrastructure to give you the research results you need. We also have permits in place to use a wide range of isotopes, including the most promising ones: 225Ac, 177Lu, 161Tb and 153Sm.
Our contract research activities are focused in three key areas:
SCK CEN specialises in radiolabelling and assists partners during the production of radioisotopes, the chemical separation or purification, the actual labelling process and its validation.
SCK CEN helps partner companies to perform both in vivo and in vitro imaging and provides access to advanced pre-clinical imaging modalities such as the SPECT-CT scanner and autoradiography scanner.
Pre-clinical & à la carte research
SCK CEN can assist with by providing you with the necessary data for the pre-clinical stage to move on to the next step in the development process. Radiopharmaceutical research can be subdivided into:
- in vitro, in vivo and ex vivo toxicology
- pharmacokinetic research
- pharmacodynamic research.
- Tailor-made projects